Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ROCKVILLE, Md., Oct. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that Thomas H. Bliss, Jr., EntreMed's Senior Vice President, Corporate and Business Development, will present a Company overview at the 16th Annual BioPartnering Europe Conference, which is being held October 12-14, 2008 in London, United Kingdom. Mr. Bliss' presentation is scheduled for Monday, October 13, 2008 at 12:15 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Bliss will provide an overview of the Company's clinical-stage programs, with particular emphasis on ENMD-2076 and 2ME2 for rheumatoid arthritis. ENMD-2076, an orally-active, Aurora/angiogenesis inhibitor for the treatment of cancer, is in a multi-center Phase 1b dose-escalation study in patients with solid tumors. Panzem(R) (2ME2), an orally-active small molecule angiogenesis inhibitor with disease modifying properties for the treatment of rheumatoid arthritis (RA), has completed a Phase 1 clinical trial in healthy volunteers. EntreMed is actively marketing ENMD-2076 and 2ME2 for RA to prospective pharmaceutical and biotech company partners as a means to accelerate the development and commercialization of these novel drug candidates.

Mr. Bliss's presentation will not be web cast; however, a copy of his presentation will be available through the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical compa
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... DELHI , April 20, 2015 ... PI3K Targeting Supramolecular Therapeutic Using the VOLVOX Platform - ... EST  -  Supramolecular Assembly of Antibody-drug ... Cytotoxic Payload - Presented on Sunday, Apr 19, 1:00 ... leader in supramolecular therapeutic program, today announced that the ...
(Date:4/20/2015)... BEIJING, April 20, 2015 Sinovac Biotech Ltd. ... China, today announced its unaudited financial results for the ... Fourth Quarter 2014 Financial Highlights(Compared to the ... $20.3 million, a decrease of 11.4% from $22.9 million ... the stockpiling of H5N1 pandemic influenza vaccine of $0.1 ...
(Date:4/20/2015)... Global Stem Cells Group ... an annual gathering of aesthetic medicine experts and innovators. ... to introduce the company’s brand new training course that ... cell techniques. , The course is designed to ... aesthetic field, including facial aging caused by volume loss. ...
(Date:4/18/2015)... , April 18, 2015 ... CRIS ) will be presenting data at ... American Associate of Cancer Research Annual Meeting (April ...      (Logo: http://photos.prnewswire.com/prnh/20130418/608115 ) , ... proprietary Nicotinamide phosphoribosyltransferase (NAMPT) small molecule inhibitors program, ...
Breaking Biology Technology:Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 2Global Stem Cells Group to Host Featured Speaker at The Aesthetic Meeting 2015 in Montreal 3Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2
... Physicians and scientists from Reproductive Medicine Associates of ... their groundbreaking research study entitled Cleavage Stage ... Blastocyst Biopsy Does Not: A Novel Paired Analysis ... The study, led by Richard T. Scott, M.D. ...
... NEW YORK, Oct. 19, 2011 Progenitor Cell Therapy ... NBS ) ("NeoStem" or the "Company"), today ... the demands associated with its contract development and manufacturing ... add to the PCT client list.  NeoStem is an ...
...  Science Applications International Corporation (SAIC) (NYSE: SAI ... the National Institute of Allergy and Infectious Diseases (NIAID), ... provide preclinical services for the development of biopharmaceutical products ... at the end of fiscal year 2011.  The total ...
Cached Biology Technology:Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 2Revolutionary IVF Study May Change the Way Embryos are Biopsied for Genetic Disease 3Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management 2Progenitor Cell Therapy, a Wholly-Owned Subsidiary of NeoStem, Inc., Announces Additions to Management 3SAIC Awarded Contract by National Institute of Allergy and Infectious Diseases 2
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... In the war against infectious disease, identifying the ... Wang and his colleagues from the Biodesign Institute at ... individual virus particles. Their research opens the door to ... may further the study of a broad range of ...
... University researchers have demonstrated a way to dramatically simplify ... New testing instrumentation developed by Antonia Garcia ... costly and produce results in less time. Current ... of working with blood, saliva, urine and other biological ...
... Ind. - A biosensor utilizing black platinum and carbon ... a better understanding of how the plant hormone auxin ... an associate professor of agricultural and biological engineering and ... movement of auxin along a plant,s root surface in ...
Cached Biology News:Visualizing viruses: new research pinpoints tiny invaders 2Visualizing viruses: new research pinpoints tiny invaders 3Health diagnosis made simpler 2Health diagnosis made simpler 3Health diagnosis made simpler 4Sensor important to understanding root, seedling development 2
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
... enclosures are designed for ... other process gas to ... HEPA filtration, heating/cooling, humidification, ... also available, along with ...
... faculty researcher, the new 4300 DNA Analysis System ... the quality of your data. High confidence in ... using LI-COR DNA analysis systems have had for ... a third generation instrument based on LI-CORs highly ...
This modular benchtop fume hood ventilates and purifies chemical fumes, allowing safe indoor release of exhaust. Bonded charcoal filters remove most organic contaminants. Options include final HEPA f...
Biology Products: